Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers.

Autor:	Amellal H; Service de Parasitologie et des Maladies Vectorielles, Institut Pasteur du Maroc, Place Louis Pasteur, 20360 Casablanca, Morocco.; Health and Environment Laboratory, Biochemistry, Biotechnology and Immunophysiopathology Research Team, Aïn Chock Faculty of Sciences, Hassan II University of Casablanca, Casablanca, Morocco., Assaid N; Service de Parasitologie et des Maladies Vectorielles, Institut Pasteur du Maroc, Place Louis Pasteur, 20360 Casablanca, Morocco., Akarid K; Health and Environment Laboratory, Biochemistry, Biotechnology and Immunophysiopathology Research Team, Aïn Chock Faculty of Sciences, Hassan II University of Casablanca, Casablanca, Morocco., Maaroufi A; Service de Parasitologie et des Maladies Vectorielles, Institut Pasteur du Maroc, Place Louis Pasteur, 20360 Casablanca, Morocco., Ezzikouri S; Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca 20360, Morocco., Sarih M; Service de Parasitologie et des Maladies Vectorielles, Institut Pasteur du Maroc, Place Louis Pasteur, 20360 Casablanca, Morocco.
Jazyk:	angličtina
Zdroj:	Vaccine: X [Vaccine X] 2023 Aug; Vol. 14, pp. 100288. Date of Electronic Publication: 2023 Mar 25.
DOI:	10.1016/j.jvacx.2023.100288
Abstrakt:	Recent studies have shown that in individuals who have received two doses of COVID-19 vaccine, the level of IgG antibodies decreased over time. In addition, the resurgence of the epidemic due to variants has led the authorities in several countries, including Morocco, to extend the third dose to the entire adult population. In this study, we included 43 healthcare workers (HCWs) who were vaccinated with three doses. They were vaccinated with ChAdOx1 nCoV-19 for the first two doses and with BNT 162b2 or BBIBP-CorV vaccine for the third dose. Humoral response was assessed on the day of injection of the third dose of vaccine and one month after the third dose by measuring anti-receptor-binding domain (RBD) IgG levels. Seven months after the second dose, the median titer of anti-RBD IgG was higher in the group with a history of SARS-CoV-2 infection than in the group with no history of infection (1038 AU/mL vs. 76.05 AU/mL, respectively, p = 0.003). One month after the third dose, a significant increase in median level of anti-RBD in both groups was observed: from 76.05 AU/mL to 6127 AU/mL in the group with no history of infection and from 1038 AU/mL to 14,412 AU/mL in the group with history of infection. Notably, the BNT 162b2 vaccine elicits a high titer of anti-RBD antibody compared to the BBIBP-CorV vaccine. Median antibody titers were 21,991 AU/mL and 3640 AU/mL for BNT 162b2 and BBIBP-CorV vaccines, respectively (p = 0.0002). 23% of HCWs were infected with SARS-CoV-2 within the first two months after the third dose injection. However, all these patients developed mild symptoms and tested negative by RT-qPCR between 10 and 15 days after the onset of symptoms. Our findings support that the third dose of COVID-19 vaccine significantly improves the humoral response and protects against the severe disease. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2023 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu